Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) EPS (Weighted Average and Diluted) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.17 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 61.36% to -$0.17 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.33 through Dec 2025, up 18.9% year-over-year, with the annual reading at -$1.33 for FY2025, 18.4% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.17 at Werewolf Therapeutics, up from -$0.36 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.95 in Q4 2021, with the low at -$83.36 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.63, with a median of -$0.4 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 99.33% in 2022, then crashed 207.14% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.95 in 2021, then tumbled by 140.0% to -$0.38 in 2022, then grew by 13.16% to -$0.33 in 2023, then tumbled by 33.33% to -$0.44 in 2024, then skyrocketed by 61.36% to -$0.17 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.17, -$0.36, and -$0.4 for Q4 2025, Q3 2025, and Q2 2025 respectively.